UPNEEQ
Peakoxymetazoline hydrochloride ophthalmic
NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2020
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 1w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UPNEEQ is an FDA-approved ophthalmic solution containing oxymetazoline hydrochloride, a selective alpha-1 adrenergic agonist indicated for treatment of acquired ptosis (drooping eyelid). It works by stimulating adrenergic receptors in the Müller muscle of the eyelid, causing contraction and elevation of the upper eyelid to improve visual field and appearance.
Peak13.6 years to LOE
Product is at peak commercial stage post-launch with stable market positioning; teams are focused on market penetration and sustained growth in the specialty ophthalmology space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
UPNEEQ represents a niche specialty ophthalmology opportunity with monopoly market positioning and long patent protection, ideal for professionals seeking stable, focused brand responsibility in a growing indication. Career growth is anchored in commercial execution, customer relationship management, and geographic expansion rather than clinical development.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.